20/20 Biolabs, Inc. Common Stock Total Assets
20/20 Biolabs, Inc. Common Stock total assets. Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) holds total assets worth $3.24 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AIDX company net worth for the company's overall valuation and market capitalisation.
Total Assets of 20/20 Biolabs, Inc. Common Stock (2016–2024)
Total assets of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024. This chart illustrates how 20/20 Biolabs, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See AIDX stock price for real-time trading data and today's change.
20/20 Biolabs, Inc. Common Stock - Asset Composition Analysis
20/20 Biolabs, Inc. Common Stock Total Assets Breakdown (December 2024)
20/20 Biolabs, Inc. Common Stock total assets breakdown as of December 2024. 20/20 Biolabs, Inc. Common Stock's total assets of $3.24 Million consist of 56.3% current assets and 43.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.4% |
| Accounts Receivable | $135.27K | 3.7% |
| Inventory | $47.16K | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $499.17K | 13.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 20/20 Biolabs, Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 20/20 Biolabs, Inc. Common Stock's current assets represent 56.3% of total assets in 2024, a decrease from 80.7% in 2016.
- Cash Position: Cash and equivalents constituted 49.4% of total assets in 2024, down from 73.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, unchanged from 13.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 13.8% of total assets.
20/20 Biolabs, Inc. Common Stock Competitors by Total Assets
Key competitors of 20/20 Biolabs, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
T&L Co. Ltd
KQ:340570
|
Korea | ₩253.22 Billion |
|
Paxman AB
ST:PAX
|
Sweden | Skr487.65 Million |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
ORTOMA AB B
F:82Y
|
Germany | €161.34 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
20/20 Biolabs, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 5.89 | 5.89 |
| Quick Ratio | 0.76 | 5.82 | 5.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-426.38K | $7.06 Million | $7.06 Million |
20/20 Biolabs, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between 20/20 Biolabs, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 472.77 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | -43.3% |
| Total Assets | $3.61 Million |
| Market Capitalization | $2.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values 20/20 Biolabs, Inc. Common Stock's assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 20/20 Biolabs, Inc. Common Stock's assets decreased by 43.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual total assets of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.61 Million | -43.26% |
| 2023-12-31 | $6.37 Million | -47.87% |
| 2022-12-31 | $12.22 Million | +18.91% |
| 2021-12-31 | $10.27 Million | +119.62% |
| 2020-12-31 | $4.68 Million | +49.63% |
| 2019-12-31 | $3.13 Million | -23.86% |
| 2018-12-31 | $4.11 Million | +188.67% |
| 2017-12-31 | $1.42 Million | +5.63% |
| 2016-12-31 | $1.35 Million | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more